Onyx Biotec Ltd IPO
Open Demat Account
Onyx Biotec Ltd IPO Details
Details
| Total Shares Offered | Offer to Public | Retail Max (Shares) | Pre Issue Promoters Holding | Exchange | Issue size |
|---|---|---|---|---|---|
| ₹ 48.1 L | TBA | ₹ 16 L | ₹ 118.03 L | NSE | ₹ 29.34 Cr |
| IPO Open Date | Close Date | Lot Size | Min Investment | Issue Type | Listing Date |
| 13 Nov, 24 | 18 Nov, 24 | 2000 | ₹ 1,16,000 | Book Building - SME | 22 Nov, 24 |
Onyx Biotec Ltd IPO Dates
Details
| Sector | Type |
|---|---|
| Sector | Pharmaceuticals - Indian - Bulk Drugs & Formln |
| Sub Sector | NA |
| Issue Type | Book Building - SME |
Subscription Status
*Values are in Lakhs
| Investor Type | Subscription Times | Shares Offered* | Shares Bid* |
|---|---|---|---|
| QIB | 13.01x | 2278000 | 29634000 |
| NII | 603.44x | 688000 | 415166000 |
| Retail | 119.36x | 1600000 | 190978000 |
| Employee | 0x | 0 | 0 |
| Total | 132.18x | 4810000 | 635778000 |
Subscription Status
Investor Type
QIB
NII
Retail
Employee
Total
*Values are in Lakhs
Onyx Biotec Ltd Financial Status
Income Statement
Balance Sheet
| Particulars (in Rs. Crores) | FY23 | FY22 | FY21 |
|---|---|---|---|
| Revenue from operations | 6.30 | 4.04 | 4.04 |
| EBITDA | 8.55 | 5.53 | 5.53 |
| PAT | 3.03 | 1.84 | 1.84 |
| Total Assets | 29.70 | 14.69 | 14.69 |
| Share Capital | 13.32 | 5.90 | 5.90 |
| Total Borrowings | 32.06 | 29.91 | 26.00 |
| Operating Activities (Net Cash) | 5.28 | 3.33 | 3.33 |
| Investing Activities (Net Cash) | 0.00 | 0.00 | 0.00 |
| Financing Activities (Net Cash) | 32.06 | 29.91 | 26.00 |
| Net Cashflow | 1.47 | 0.01 | 0.01 |
Particulars (in Rs. Crores)
Revenue from operations
EBITDA
PAT
Total Assets
Share Capital
Total Borrowings
Operating Activities (Net Cash)
Investing Activities (Net Cash)
Financing Activities (Net Cash)
Net Cashflow
About Onyx Biotec Ltd
Onyx Biotec Limited (the Company or the Issuer) was incorporated on May 13, 2005 as a private limited company as `Onyx Biotec Private Limited', under the Companies Act, 1956, pursuant to a certificate of incorporation dated May 13, 2005 issued by the Registrar of Companies, Punjab, H.P. & Chandigarh. Further, our Company was converted into a public limited company pursuant to a resolution passed by our Board of Directors in its meeting held on May 1, 2024, and by the Shareholders in an Extraordinary General Meeting held on May 27, 2024 and consequently the name of our Company was changed to `Onyx Biotec Limited' and a fresh certificate of incorporation dated July 23, 2024 was issued by the Registrar of Companies, Central Processing Centre.
According to a recent EY FICCI report, as there has been a growing consensus over providing new innovative therapies to patients, Indian pharmaceutical market is estimated to touch US$ 130 billion in value by the end of 2030 and US$ 450 billion market by 2047. India ranks 3rd worldwide for pharmaceutical production by volume and 14th by value. The country has an established domestic pharmaceutical industry, with a strong network of 3,000 drug companies and ~10,500 manufacturing units. India's drugs and pharmaceuticals exports stood at US$ 27.82 billion in FY24 (April- March). According to Government data, the Indian pharmaceutical industry is worth approximately US$ 50 billion with over US$ 25 billion of the value coming from exports. About 20% of the global exports in generic drugs are met by India. During FY18 to FY23, the Indian pharmaceutical industry logged a compound annual growth rate (CAGR) of 6-8%, primarily driven by an 8% increase in exports and a 6% rise in the domestic market. The Indian pharmaceutical industry has seen a massive expansion over the last few years and is expected to reach about 13% of the size of the global pharma market while enhancing its quality, affordability, and innovation. Indian pharmaceutical sector is expected to grow at a CAGR of 22.4% in the near future. The government has set ambitious target to boost the medical devices industry in India, aiming to elevate it from its current US$ 11 billion valuation to US$ 50 billion by 2030. India is the second-largest contributor of global biotech and pharmaceutical workforce. Exports of drugs and pharmaceuticals recorded a strong y-o-y growth of 9.7% during April- March FY24.
Onyx started its operation in pharmaceutical industry with sterile water for injections in the year 2010. Since then, Onyx has been associated with the healthcare segment and offering Sterile Pharmaceutical products and has become a prominent supplier of sterile products to major corporations, which includes the top pharma companies at pan India level. Onyx is committed to provide high-quality products at affordable price. Presently, our Company manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas. Our products are being processed and manufactured in accordance with best FDA practices available globally. Our system and product is tested constantly at each level to ensure international standards of quality in-house and FDA Certified Laboratories. Our core business is focused on providing end-to-end product development and manufacturing solutions to our clients. Our service also include preparation and filing of regulatory dossiers in the Indian and global markets.
Peer Comparison:
- Suven Pharmaceuticals Ltd
- J B Chemicals & Pharmaceuticals Ltd
Onyx Biotec Ltd IPO Key Points
Strengths
- One of the prominent contract manufacturers in sterile manufacturing.
- Quality Assurance and Quality Control of our products.
- Strong, cordial & long-term relationship with our Marque Clientele.
- Cost effective production and timely fulfilment of orders.
- Well experienced management team with proven project management and implementation skills.
Risk
- Its manufacturing units are concentrated in Solan, Himachal Pradesh, and the company is exposed to risks originating from economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect its business, results of operations and financial condition.
- Any slowdown or shutdown in its manufacturing operations could have an adverse effect on its business, results of operations, financial condition and cash flows.
- Any manufacturing or quality control concerns or its inability to deliver products on a timely basis, or at all, could result in the cancellation of purchase orders, breaches of relevant agreements, and termination of agreements by its clients and distributors, which could have an adverse effect on its business, results of operations, financial condition and cash flows.
Strategy
- Market Penetration and Geographic Expansion.
- Leverage our position as a contract manufacturer for pharmaceutical companies.
- Leverage our position in the loan licencing to the pharma companies.
- Focus on our Quality Control.
- Growing our business with existing clients with quality products.
- One of the prominent contract manufacturers in sterile manufacturing.
- Quality Assurance and Quality Control of our products.
- Strong, cordial & long-term relationship with our Marque Clientele.
- Cost effective production and timely fulfilment of orders.
- Well experienced management team with proven project management and implementation skills.
How To Apply for Onyx Biotec Ltd IPO Online?
Step 1:
Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.
Step 2:
From the list of open IPOs, select the IPO you want to invest.
Step 3:
Go through the IPO details like lot size, price band, about the company, etc.
Step 4:
Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.
Step 5:
Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.